Cited 0 time in
PIK3CG, PRKCD, and TRIM22: Concurrent Regulators of Poor Prognosis and Enhanced Immune Activity in Glioblastoma - Multi-Omics Identification and Therapeutic Implications
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 한명훈 | - |
| dc.date.accessioned | 2026-07-08T23:00:53Z | - |
| dc.date.available | 2026-07-08T23:00:53Z | - |
| dc.date.issued | 2025-10-18 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/218589 | - |
| dc.title | PIK3CG, PRKCD, and TRIM22: Concurrent Regulators of Poor Prognosis and Enhanced Immune Activity in Glioblastoma - Multi-Omics Identification and Therapeutic Implications | - |
| dc.type | Conference | - |
| dc.citation.conferenceName | 第63回 日本癌治療学会 学術集会 (The 63rd Annual Meeting of Japan Society of Clinical Oncology, JSCO 2025) | - |
| dc.citation.conferencePlace | パシフィコ横浜 (Pacifico Yokohama) 1F 展示ホール B | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
